Abstracts tagged "Juvenile idiopathic arthritis-enthesitis (ERA)"

Abstract Number: 123 • 2020 Pediatric Rheumatology Symposium
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
Dax Rumsey¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Laura Schanberg ⁴, Jennifer Schenfeld ⁵, Natalie Shiff ⁶, Matthew Stoll ⁷, Scott Stryker ⁸, Pamela Weiss ⁹ and Timothy Beukelman ⁷ for the CARRA investigators, ¹University of Alberta, Edmonton, Canada, ²Duke University, Durham, ³Amgen, Thousand Oaks, ⁴Duke Children's Hospital & Health Center, Durham, North Carolina, ⁵Amgen, Long Beach, ⁶Florida, Gainesville, ⁷University of Alabama at Birmingham, Birmingham, ⁸Amgen, Inc, San Francisco, ⁹Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: To describe characteristics of children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA)…
Abstract Number: 2709 • 2019 ACR/ARP Annual Meeting
Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index
Ivan Foeldvari¹ and Jean Baer ¹, ¹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Secukinumab (SEC) is licensed to treat adults with spondyloarthritis and psoriatic arthritis. It is not licensed for juvenile patients yet. As biologic agents up…
Abstract Number: 2713 • 2019 ACR/ARP Annual Meeting
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
Dax Rumsey¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Laura Schanberg ⁴, Jennifer Schenfeld ⁵, Natalie Shiff ⁶, Matthew Stoll ⁷, Scott Stryker ³, Pamela F. Weiss ⁸ and Timothy Beukelman ⁹, ¹University of Alberta, Edmonton, AB, Canada, ²Duke University, Durham, NC, ³Amgen Inc., Thousand Oaks, CA, ⁴Duke University Medical Center, Durham, NC, ⁵Amgen, Inc, Thousand Oaks, CA, ⁶University of Florida, Gainesville, FL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹University of Alabama Birmingham, Birmingham, AL
Background/Purpose: Herein we describe characteristics of children with juvenile spondyloarthritis (JSpA, i.e. enthesitis-related arthritis [ERA] or juvenile psoriatic arthritis [JPsA]) enrolled in the Childhood Arthritis…
Abstract Number: 1436 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Partners of DMARD Exposed Men with Juvenile Idiopathic Arthritis – an Observational Study
Paula Drechsel¹, Jens Klotsche², Martina Niewerth², Gerd Horneff³ and Kirsten Minden⁴, ¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Asklepios Clinic Sankt Augustin, and University Hospital of Cologne, Cologne, Germany, ⁴Epidemiology unit, German Rheumatism Research Center and Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Males account for about one third of all cases of juvenile idiopathic arthritis (JIA). During the course of the disease and often into adulthood,…
Abstract Number: 2386 • 2018 ACR/ARHP Annual Meeting
Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment
Ivan Foeldvari and Jean Baer, Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany
Background/Purpose: Secukinumab (SEC) is licensed to treat adults with spondyloarthritis. It is not licensed for pediatric patients with Juvenile Idiopathic Enthesitis related Arthritis (enthJIA) yet.…
Abstract Number: 2288 • 2017 ACR/ARHP Annual Meeting
Successful Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR)
Lea Höfel, Bruno Eppler, Elisabeth Schnöbel-Müller, Johannes Peter Haas and Boris Hügle, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany
Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of children with juvenile idiopathic arthritis (JIA). It frequently has to be discontinued due to intolerance…
Abstract Number: 2296 • 2017 ACR/ARHP Annual Meeting
Infliximab Use in JIA and Uveitis: Does Methotrexate Help or Hinder?
Ryan Funk¹, Valentina Shakhnovich², Leon van Haandel³ and Mara L Becker⁴, ¹University of Kansas Medical Center, Kansas City, KS, ²Gastroenterology and Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, ³Clinical Pharmacology, Medical Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Infliximab (IFX) effectiveness is impacted in part by immunogenicity and the development of drug neutralizing anti-drug antibodies, thus methotrexate is commonly co-administered to minimize…
Abstract Number: 2329 • 2017 ACR/ARHP Annual Meeting
Monocytes from Patients with Enthesitis Related Arthritis Produce High Levels of Pro-Inflammatory Cytokines: Role of Endogenous Ligands
Amita Aggarwal¹, Shruti Bhattacharya² and Ramnath Misra², ¹Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: HLA B27 and gut bacteria are postulated to play a role in pathogenesis of Enthesitis Related Arthritis. Gut microbes can activate monocytes/macrophages by TLR…
Abstract Number: 2333 • 2017 ACR/ARHP Annual Meeting
Adjudication of Infections from the Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate with a Focus on Opportunistic Infections
Joost Swart¹, Gabriella Giancane^1,2, Elio Castagnola¹, Andreas Groll¹, Gerd Horneff¹, Hans-Iko Huppertz¹, Daniel J Lovell³, Tom Wolfs¹, Michaël Hofer¹, Ekaterina Alexeeva¹, Violeta Vladislava Panaviene¹, Susan Nielsen¹, Jordi Anton¹, Florence Uettwiller¹, Valda Stanevicha¹, Maria Trachana¹, Fabrizio De Benedetti¹, Constantin Ailioaie¹, Elena Tsitsami¹, Sylvia S.M. Kamphuis¹, Troels Herlin¹, Pavla Dolezalová¹, Gordana Susic¹, Berit Flato¹, Flavio Sztajnbok¹, Elena Fueri⁴, Francesca Bovis⁵, Francesca Bagnasco¹, Angela Pistorio¹, Alberto Martini⁶, Nico Wulffraat⁷ and Nicolino Ruperto⁶, ¹Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ²Pediatria II, Reumatologia - PRINTO, Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ³Rheumatology, PRCSG - Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁴Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ⁵Università degli Studi di Genova, Genoa, Italy, ⁶Istituto Giannina Gaslini, Genoa, Italy, ⁷Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Pharmachild is a pharmacovigilance registry on children with JIA treated mainly with biologics ± methotrexate (MTX). Little evidence exists in literature about the role…
Abstract Number: 950 • 2016 ACR/ARHP Annual Meeting
Flares after Withdrawal of Biotherapies in JIA: Clinical and Laboratory Correlates of Remission Duration
Gabriele Simonini¹, Erika Scoccimarro¹, Irene Pontikaki², Giovanna Ferrara³, Teresa Giani¹, Andrea Taddio³, Pier Luigi Meroni⁴ and Rolando Cimaz¹, ¹Pediatric Rheumatology Unit, Anna Meyer Children's Hospital-University of Florence, Firenze, Italy, ²Rheumatology Department, Gaetano Pini Institute, University of Milan, Milano, Italy, ³Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", University of Trieste, Trieste, Italy, ⁴Rheumatology Department, University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy
Background/Purpose: Information regarding the history of patients with JIA after systemic treatment withdrawal would be helpful in driving the choice of duration therapy. While some…
Abstract Number: 1455 • 2015 ACR/ARHP Annual Meeting
Juvenile Spondyloarthropathies: a Single Center Experience
Kenan Barut¹, Metin Sezen², Sezgin Sahin³, Amra Adrovic³, Serdal Ugurlu⁴, Huri Ozdogan⁵ and Ozgur Kasapcopur⁶, ¹Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University., Fellow in Pediatric Rheumatology, Istanbul, Turkey, ²Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey, ³Department of Pediatric Rheumatology, Cerrahpaşa Medical School, Istanbul University., Fellow in Pediatric Rheumatology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁶Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Professor of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: : Juvenile spondyloarthropathies (JSpA) are a group of chronic childhood rheumatic diseases which emerge especially before 16 and after 6 years-old. While enthesitis and…
Abstract Number: 2451 • 2015 ACR/ARHP Annual Meeting
Scoring Medication Requirements and Side-Effects in Juvenile Idiopathic Arthritis: Perspectives of Patients, Parents and Clinicians
Lori B. Tucker¹, Natalie Shiff², Susanne Benseler³, Roberta Berard⁴, Roman Jurencak⁵, Thomas Loughin⁶, Jaime Guzman⁷ and Andrew Henrey⁶, ¹Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ²Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ³Pediatrics, University of Calgary, Toronto, ON, Canada, ⁴Children's Hospital of Western Ontario, London, ON, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, ⁷Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Medication requirements (MedReq) and medication side effects (MedSE) were found to be top priorities by patients, parents and clinicians in describing the course of…
Abstract Number: 2288 • 2014 ACR/ARHP Annual Meeting
The Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Independent Risk Factors and Medication Use in New Onset Uveitis in Juvenile Idiopathic Arthritis
Jennifer JY Lee¹, Ciarán M. Duffy², Jaime Guzman³, Nick Barrowman⁴, Deepti Reddy⁴, Kimberly Morishita⁵, Lynn R. Spiegel⁶, Elizabeth Stringer⁷, Michele Gibbon², Rae S.M. Yeung⁸, Lori B. Tucker³, Kiem Oen⁹, Karen N Watanabe Duffy² and ReACChOut Investigators², ¹Pediatrics, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ²Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ³Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁴Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ⁵BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁶The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁷Department of Rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁸Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: The Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh Out) cohort is a multi-centre prospective inception cohort of newly diagnosed Juvenile Idiopathic Arthritis…
Abstract Number: L14 • 2014 ACR/ARHP Annual Meeting
Determination of Efficacy of Intra-Articular Infliximab Therapy in JIA Patients By 3D/4D Musculo-Skeletal Ultrasound
Miroslav Harjacek¹, Mandica Vidovic², Lovro Lamot^2,3, Marija Perica² and Lana Tambic Bukovac², ¹Rheumatology, Children's Hospital Srebrnjak, Zagreb, Croatia, ²Children's Hospital Srebrnjak, Zagreb, Croatia, ³University of Zagreb School of Medicine, Zagreb, Croatia
Background/Purpose: Intra-articular (IA) infliximab (IFX) is an attractive treatment option of chronic arthritis, but based on few heterogenic studies, outcome is still controversial. To investigate…
Abstract Number: 2789 • 2013 ACR/ARHP Annual Meeting
Enhancing Uveitis Screening Compliance In Juvenile Idiopathic Arthritis Patients
Melissa S Oliver¹, Jennifer E. Weiss², Suzanne C. Li³, Kathleen A. Haines², Ginger L. Janow², Esi Morgan DeWitt⁴ and Yukiko Kimura², ¹Pediatrics, UMDNJ New Jersey Medical School, Newark, NJ, ²Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ³Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁴Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Chronic uveitis is one of the more severe morbidities associated with juvenile idiopathic arthritis (JIA). Risk of developing uveitis, and the frequency of uveitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].